We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Novavax announced Wednesday that it has reached an agreement with Australia that will see the company supply 40 million doses of its COVID-19 vaccine candidate for the country. Read More
UK Vaccine Taskforce Chairwoman Kate Bingham revealed Wednesday that the country will have millions fewer doses of AstraZeneca’s vaccine candidate available by the end of the year than previously anticipated. Read More
Novartis has announced that effective Nov. 16, it will remove discounts for hospitals enrolled in the 340B Drug Pricing Program for products dispensed at pharmacies that are more than 40 miles from a hospital’s main facility. Read More
In an unusual move, the FDA has removed an advisory committee member temporarily, just days before a critical vote on an investigational treatment for Alzheimer’s disease. Read More
The Coalition for Epidemic Preparedness Innovations (CEPI) has agreed to fund development of a potential COVID-19 vaccine from China’s Clover Biopharmaceuticals with a global phase 2/3 study and through licensing and distribution. Read More
Gilead Sciences says it has no plans to relinquish the Priority Review voucher it earned from the FDA’s approval of remdesivir as a COVID-19 treatment despite urging from a consumer advocacy group that argued the company is earning more than is reasonable from the antiviral. Read More
Pfizer said it intends to handle the distribution of its COVID-19 vaccine itself after the federal government’s initial distribution to priority populations is completed. Read More